CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
ongoing trials trial from www.clinicaltrials.gov

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa - Phase 1|Phase 2 - Not yet recruiting

  • Year: 2022
  • Date: July 12, 2022
  • Author: National Institute of Allergy and Infectious Diseases (NIAID)
Source

https://ClinicalTrials.gov/show/NCT05453578

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment

Participants

Bacterial Disease Carrier|Cystic Fibrosis - 18 Years to 99 Years   (Adult, Older Adult)

Interventions

Other: Placebo|Biological: WRAIR_PAM-CF1

Outcome measures

Change from baseline in log10 P. aeruginosa total colony counts in quantitative sputum cultures|Desirability of Outcome Ranking (DOOR)|Number of grade 2 or higher treatment-emergent Adverse Events

Related topics

Antibiotic treatment for stenotrophomonas maltophilia in people with cystic fibrosis

Antibiotic treatment of early pseudomonas aeruginosa

Antibiotics for pulmonary exacerbations

Inhaled antibiotics in cystic fibrosis

MRSA eradication in CF

Prophylactic use of oral antistaphylococcal antibiotic

Scheduled antibiotics every 3-4 months / symptom-based treatment

Keywords: Phage therapy; Anti-bacterial agents; pharmacological_intervention; Bacterial Infections; Infection; Inhalation OR nebulised; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections;